Core Insights - Bionano Genomics participated in the ESHG conference, showcasing the effectiveness of optical genome mapping (OGM) in genetic disease research, particularly in detecting structural variants (SVs) related to various genetic disorders [1][4] Group 1: Conference Highlights - The ESHG 2025 conference featured 21 studies from 12 countries, demonstrating OGM's capability in identifying SVs often missed by traditional methods, highlighting its potential in addressing complex genetic conditions [2][4] - Dr. Erik Holmlin, CEO of Bionano, emphasized the growing recognition of OGM within the global scientific community, indicating a significant number of presentations and posters that support OGM's capabilities [4] Group 2: Scientific Contributions - Notable presentations included studies on gene-pseudogene inversions, mobile element insertions in diseases, and the use of OGM in pediatric gliomas and hematological malignancies, showcasing the diverse applications of OGM in genetic research [3][4] - The integration of short and long-read genome sequencing with OGM was highlighted as a method for discovering complex genomic rearrangements, further illustrating OGM's diagnostic utility [4] Group 3: Company Overview - Bionano Genomics provides genome analysis solutions aimed at transforming genomic research through OGM technology, diagnostic services, and software, catering to various research applications [6] - The company also offers OGM-based diagnostic testing services through its subsidiary, Lineagen, Inc., enhancing its position in the genomic analysis market [6]